Information Journal Paper
APA:
Copy. (2018). Phase I Trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. CELL STEM CELL, 22(6), 951-959. SID. https://sid.ir/paper/766228/en
Vancouver:
Copy. Phase I Trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. CELL STEM CELL[Internet]. 2018;22(6):951-959. Available from: https://sid.ir/paper/766228/en
IEEE:
Copy, “Phase I Trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia,” CELL STEM CELL, vol. 22, no. 6, pp. 951–959, 2018, [Online]. Available: https://sid.ir/paper/766228/en